Researchers at Yashraj Biotechnology Ltd.-IDD highlight the transformative role of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in cardiovascular research and translational medicine. These advanced cell models provide a human-relevant platform for disease modeling, drug discovery, cardiotoxicity screening, and regenerative medicine applications.

The article discusses key methodologies for generating high-purity cardiomyocytes, strategies to improve cellular maturation, and the importance of standardization for reproducible drug screening studies. It further explores the integration of CRISPR/Cas9 technology for precision medicine, enabling patient-specific disease modeling and personalized therapeutic approaches.

Through case studies including Long QT Syndrome and Doxorubicin-induced cardiotoxicity, the review demonstrates the practical value of hiPSC-CMs in understanding disease mechanisms and predicting drug safety. The article also highlights recent advances in engineered heart tissues, regulatory acceptance through the CiPA initiative, and future opportunities in personalized cardiovascular medicine.